Nexium Direct Purchasers Win Class Cert. In Antitrust MDL

Law360, New York (December 11, 2013, 5:25 PM ET) -- A Massachusetts judge granted class certification on Wednesday to a group of direct purchasers alleging AstraZeneca PLC and others breached antitrust laws by engineering the delay of a generic form of heartburn drug Nexium.

U.S. District Judge William G. Young noted that the defendants raised many of the same objections in their efforts to avoid certification of a class of end-buyers he approved in mid-November, and said the same analysis applies “with full force and effect” to the direct purchasers’ certification bid.

The direct purchasers claim...
To view the full article, register now.